Boyu Capital
VC Fund
Beijing, China
Boyu Capital is a VC fund in Beijing focused on Biotechnology and Health Care. Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
- Total investments:
- 99
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $3.6B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Boyu Capital invests in
Stages Boyu Capital invests in
Countries Boyu Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.6M–$500M
- Series A
- $15M–$500M
- Series C
- $28M–$283M
Investment Focus
Industry
- Biotechnology 20 (20%)
- Health Care 17 (17%)
- Medical 9 (9%)
- Artificial Intelligence 8 (8%)
- E-Commerce 7 (7%)
Stage
- Series A 23 (23%)
- Series C 11 (11%)
- Seed 9 (9%)
- Series B 9 (9%)
- Series D 9 (9%)
Country
- China 61 (62%)
- United States 9 (9%)
- Hong Kong 3 (3%)
- Singapore 2 (2%)
- Indonesia 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Mary Ma
Co-Founder and Chairman
|
Co-Founder and Chairman | Total investments: 0 | Find email | |
|
Yanling Cao
Managing Director
|
Managing Director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Manus is a general AI agent that bridges thoughts and actions by excelling in various tasks such as research, data analysis, education, and productivity, offering personalized solutions across different domains to help users achieve their goals efficiently. | $500M / Venture - Series Unknown / Oct 08, 2026 | ||
| Anew Labs develops generative AI platforms and foundation models to accelerate drug discovery, including protein structure prediction, antibody design, and cellular dynamics forecasting. The company integrates its computational engines with experimental feedback to advance pipelines targeting diseases like inflammatory conditions. Its business model centers on side-by-side collaboration between machine learning researchers and biotechnology experts to create synthesizable molecular pathways and clinical candidates. | $290M / Series A / Sep 16, 2026 | ||
| ACE Studio is an AI-powered vocal synthesis and music production platform generating studio-quality singing and instruments. | $40M / Series B / Sep 03, 2026 | ||
| XTEINK is an e-ink screen that magnetically attaches to the back of your phone. | $7.4M / Series A / Aug 11, 2026 | ||
| Hefei Blue Star Technology is a high-tech enterprise specializing in the research and development of stellarator technology. | Angel / Aug 04, 2026 | ||
|
Futuring Robot
|
Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios. | $147.7M / Seed / Jul 22, 2026 | |
|
Endless Ark
|
Endless Ark focuses on anti-aging drug development, innovatively integrating artificial intelligence algorithms with cross-species biological data. | Seed / Jul 01, 2026 | |
| EonArk develops an artificial intelligence platform utilizing cross-species genomic and single-cell transcriptomic data to map, model, and target the biological aging process. The company builds specialized longevity foundation models and transfer learning frameworks to evaluate cross-organ data and identify multi-gene networks for anti-aging drugdiscovery. To support its developmental data loop, the platform leverages companion animal methylation testing for biological age and genetic risk assessments as an early commercial monetization channel. | Seed / Jul 01, 2026 | ||
| LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need. | $38M / Series B / May 06, 2026 | ||
| XTEINK is an e-ink screen that magnetically attaches to the back of your phone. | $14.6M / Series A / Apr 24, 2026 | ||
| See all 99 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Boyu Capital invest in?
Boyu Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series C stage. Most of the 99 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Boyu Capital invest in?
Boyu Capital typically joins rounds of $2.6M–$500M at Seed, $15M–$500M at Series A and $28M–$283M at Series C. These are whole funding-round sizes, not Boyu Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Boyu Capital took part in.
How do I contact Boyu Capital?
Public channels for Boyu Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Boyu Capital?
The team at Boyu Capital includes Mary Ma (Co-Founder and Chairman) and Yanling Cao (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
